A fundamental analysis of UnitedHealth Group (UNH) covering revenue trends, profitability, dividends, balance sheet health, and valuation.
UnitedHealth Group's Revenue Performance
In FY2025, UnitedHealth Group posted revenue of $447.57B, up 11.8% from $400.28B a year earlier.
A 11.0% CAGR over 10 years puts UnitedHealth Group in solid growth territory. The top line went from $157.11B to $447.57B in that span.
In terms of scale, UnitedHealth Group's $447.57B in annual revenue positions it as a large-cap health care company.
UnitedHealth Group has posted revenue growth for 10 consecutive years, that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | $447.57B | +11.8% |
| FY2024 | $400.28B | +7.7% |
| FY2023 | $371.62B | +14.6% |
| FY2022 | $324.16B | +12.7% |
| FY2021 | $287.60B | +11.8% |
View the detailed revenue trend and growth analysis
Revenue by Segment
UnitedHealth Group reports revenue across 4 product segments. Here's the FY2025 breakdown.
Revenue by Product Segment (FY2025)
| Segment | Revenue | % of Total |
|---|---|---|
| UnitedHealthcare | $342.73B | 77.3% |
| Optum Rx | $57.68B | 13.0% |
| Optum Health | $36.87B | 8.3% |
| Optum Insight | $6.37B | 1.4% |
UnitedHealthcare makes up 77.3% of revenue, clearly the primary business for UnitedHealth Group.
Profitability
Net income for UnitedHealth Group weakened to $12.06B in FY2025, 16.3% lower than the $14.40B posted in FY2024.
Margin pressure was evident, with net margin declining to 2.7% from 3.6%.
On a per-share basis, diluted earnings were $13.23 in FY2025 versus $15.51 in FY2024.
Explore the profitability trend in detail below
UnitedHealth Group Shareholder Returns
Shareholders received $8.70 per share in dividends during FY2025, a yield of about 2.07%.
The dividend track record is notable: UnitedHealth Group has maintained payouts for 10+ straight years.
The 65.8% payout ratio suggests the dividend is comfortably covered by earnings, with room to grow.
| Year | DPS | Payout Ratio |
|---|---|---|
| FY2025 | $8.70 | 65.8% |
| FY2024 | $8.11 | 52.3% |
| FY2023 | $7.21 | 30.2% |
| FY2022 | $6.31 | 29.8% |
| FY2021 | $5.52 | 30.5% |
UnitedHealth Group has been actively repurchasing shares, spending $52.77B on buybacks over the past 11 years.
See UnitedHealth Group's buyback history alongside shares outstanding below
UnitedHealth Group's Balance Sheet Health
| Metric | Value |
|---|---|
| Cash & Short-term Investments | $28.12B |
| Total Debt | $78.39B |
| Shareholders' Equity | $94.11B |
| Total Assets | $309.58B |
| Debt-to-Equity Ratio | 0.83x |
| Current Ratio | 0.79x |
| Interest Coverage | 4.7x |
| Free Cash Flow (TTM) | $16.07B |
UnitedHealth Group has a debt-to-equity ratio of 0.83, a current ratio of 0.79, interest coverage of 4.7x in FY2025, which suggest adequate financial health with manageable leverage.
UnitedHealth Group carries significant leverage with $78.39B in total debt against $94.11B in equity (D/E: 0.83x). The $28.12B cash position provides some buffer.
The current ratio of 0.79x is on the lower side, suggesting UnitedHealth Group's short-term liquidity bears watching.
At 4.7x interest coverage, UnitedHealth Group has substantial headroom above its debt payments.
Strong free cash flow generation of $16.07B gives UnitedHealth Group financial flexibility for capital allocation.
Explore UnitedHealth Group's full balance sheet and cash flow analysis below
As of FY2025, UnitedHealth Group's workforce stood at 390,000, about $1.1M in revenue per employee.
See UnitedHealth Group's full employee count history and revenue per employee
Valuation Check: Is UnitedHealth Group Overpriced?
Is UnitedHealth Group overvalued? Let's see what the numbers say.
UnitedHealth Group shares are currently trading at $415.36.
Running the numbers through the P/E Ratio model gives a fair value of $297 for UnitedHealth Group.
We also calculate intrinsic value using the DCF and EPS Growth models. Sign up to see the full breakdown with fair value estimates.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | $297 | 40.0% downside to fair value |
| DCF | Upgrade | Upgrade |
| EPS Growth | Upgrade | Upgrade |
Key Takeaways
To sum up UnitedHealth Group's financial position: the data paints a clear picture for investors evaluating this health care stock.
Revenue of $447.57B in FY2025, up 11.8% year-over-year.
Long-term revenue has been compounding at 11.0% annually over 10 years.
The company is profitable, with a net margin of 2.7% and net income of $12.06B.
Returned $13.46B to shareholders in FY2025 through dividends and/or buybacks.
Conservative balance sheet with a D/E ratio of 0.83x.
The P/E Ratio model implies 40.0% downside to fair value. The remaining 2 models are worth cross-checking before drawing a conclusion. Sign up to see the full analysis.
Explore UnitedHealth Group's complete financial data, including valuation models and historical trends, in the charts below.